Cost-Effectiveness of PCSK9 inhibitor therapy in patients with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease

JAMA - Journal of the American Medical Association

Volumn 316, Issue 7, 2016, Pages 743-753

  Kazi, Dhruv S ^a   Moran, Andrew E ^a   Coxson, Pamela G ^a   Penko, Joanne ^a   Ollendorf, Daniel A ^a   Pearson, Steven D ^a   Tice, Jeffrey A ^a   Guzman, David ^a   Bibbins Domingo, Kirsten ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALIROCUMAB; EVOLOCUMAB; EZETIMIBE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9 INHIBITOR; SERINE PROTEINASE INHIBITOR; UNCLASSIFIED DRUG; HYPOCHOLESTEROLEMIC AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MONOCLONAL ANTIBODY; PCSK9 PROTEIN, HUMAN; SERINE PROTEINASE;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CORONARY ARTERY ATHEROSCLEROSIS; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DRUG COST; ECONOMIC EVALUATION; FAMILIAL HYPERCHOLESTEROLEMIA; FEMALE; HEALTH CARE COST; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; SIMULATION; UNITED STATES; AGED; ANTAGONISTS AND INHIBITORS; ATHEROSCLEROSIS; BLOOD; CARDIOVASCULAR DISEASES; COST BENEFIT ANALYSIS; ECONOMICS; HYPERLIPOPROTEINEMIA TYPE II; UNCERTAINTY; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTICHOLESTEREMIC AGENTS; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASES; CHOLESTEROL, LDL; COST-BENEFIT ANALYSIS; DRUG COSTS; EZETIMIBE; FEMALE; HUMANS; HYPERLIPOPROTEINEMIA TYPE II; MALE; MIDDLE AGED; PROPROTEIN CONVERTASES; QUALITY-ADJUSTED LIFE YEARS; SERINE ENDOPEPTIDASES; UNCERTAINTY; UNITED STATES;

EID: 84987653542     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2016.11004     Document Type: Article

References (58)

1. Giugliano RP, SabatineMS. Are PCSK9 inhibitors the next breakthrough in the cardiovascular field J AmColl Cardiol. 2015;65(24):2638-2651.
2. Hunt SC, Hopkins PN, Bulka K, et al. Genetic localization to chromosome 1p32 of the third locus for familial hypercholesterolemia in a Utah kindred. Arterioscler Thromb Vasc Biol. 2000;20(4):1089-1093.
3. Cohen J, Pertsemlidis A, Kotowski IK, et al. Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9. Nat Genet. 2005;37(2):161-165.
4. Navarese EP, Kolodziejczak M, Schulze V, et al. Effects of proprotein convertase subtilisin/kexin type 9 antibodies in adults with hypercholesterolemia: a systematic review and meta-analysis. Ann Intern Med. 2015;163(1):40-51.
5. Tice JA, Kazi D, Ollendorf DA, et al. PCSK9 Inhibitors for Treatment of High Cholesterol: Effectiveness, Value, and Value-Based Price Benchmarks Draft Report. Boston, MA: Institute for Clinical and Economic Review; September 8, 2015.
6. Moran AE, Odden MC, Thanataveerat A, et al. Cost-effectiveness of hypertension therapy according to 2014 guidelines. N Engl J Med. 2015; 372(5):447-455.
7. Bibbins-Domingo K, Coxson P, Pletcher MJ, Lightwood J, Goldman L. Adolescent overweight and future adult coronary heart disease. N Engl J Med. 2007;357(23):2371-2379.
8. Weinstein MC, Coxson PG,Williams LW, et al. Forecasting coronary heart disease incidence, mortality, and cost. Am J Public Health. 1987;77(11): 1417-1426.
9. National Center for Health Statistics. National Health and Nutrition Examination Survey, 2005-2012. http://www.cdc.gov/nchs/nhanes/nhanes-questionnaires.htm. Accessed June 8, 2015.
10. GoldMR, Siegel JE, Russel LB, eds. Cost-Effectiveness in Health and Medicine. New York, NY: Oxford University Press; 1996.
11. Ara R, Tumur I, Pandor A, et al. Ezetimibe for the treatment of hypercholesterolaemia. Health Technol Assess. 2008;12(21):iii, xi-xiii, 1-212.
12. Mikhailidis DP, Sibbring GC, Ballantyne CM, et al.Meta-analysis of the cholesterol-lowering effect of ezetimibe added to ongoing statin therapy. Curr Med Res Opin. 2007;23(8):2009-2026.
13. Fulcher J, O'Connell R, VoyseyM, et al. Efficacy and safety of LDL-lowering therapy among men and women. Lancet. 2015;385(9976):1397-1405.
14. Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med. 2015;372(25): 2387-2397.
15. Blom DJ, Hala T, Bolognese M, et al. A 52-week placebo-controlled trial of evolocumab in hyperlipidemia. N Engl J Med. 2014;370:1809-1819.
16. Giugliano RP, Desai NR, Kohli P, et al. Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57). Lancet. 2012;380(9858):2007-2017.
17. Moriarty PM, Thompson PD, Cannon CP, et al. Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm. J Clin Lipidol. 2015;9(6):758-769.
18. Kereiakes DJ, Robinson JG, Cannon CP, et al. Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab among high cardiovascular risk patients on maximally tolerated statin therapy. Am Heart J. 2015;169(6): 906-915.
19. Cannon CP, Cariou B, Blom D, et al. Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins. Eur Heart J. 2015;36(19):1186-1194.
20. Kastelein JJ, Ginsberg HN, Langslet G, et al. ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia. Eur Heart J. 2015;36(43):2996-3003.
21. Robinson JG, FarnierM, Krempf M, et al. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015;372 (16):1489-1499.
22. Bays H, Gaudet D,Weiss R, et al. Alirocumab as add-on to atorvastatin vs other lipid treatment strategies. J Clin Endocrinol Metab. 2015;100(8): 3140-3148.
23. Farnier M, Jones P, Severance R, et al. Efficacy and safety of adding alirocumab to rosuvastatin vs adding ezetimibe or doubling the rosuvastatin dose in high cardiovascular-risk patients. Atherosclerosis. 2016;244:138-146.
24. Raal FJ, Honarpour N, Blom DJ, et al. Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B). Lancet. 2015;385(9965):341-350.
25. SabatineMS, Giugliano RP,Wiviott SD, et al. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015;372 (16):1500-1509.
26. Truven Health Analytics. Red Book Online. http://www.redbook.com/redbook/about. Accessed July 1, 2015.
27. California Public Patient Discharge Data, 2008. Sacramento, CA: Office of Statewide Health Planning and Development; 2008.
28. Hospital Financial Data, 1999-2000. Sacramento, CA: Office of Statewide Health Planning and Development; 2003. http://www .oshpd.ca.gov/HID/Hospital-Financial.asp#Profile. Accessed January 1, 2016.
29. US Census Bureau. Statistical Abstract of the United States: Average Cost to Community Hospitals Per Patient, by State (Table 204).Washington, DC: Government Printing Office; 1998:136.
30. Bureau of Labor Statistics. Consumer Price Index for All Urban Consumers. http://data.bls.gov/cgi-bin/surveymostcu. Accessed July 15, 2015.
31. Agency for Healthcare Research and Quality. Medical Expenditure Panel Survey public use files 1998-2008. http://meps.ahrq.gov/mepsweb/. Accessed January 1, 2015.
32. Moran AE, Forouzanfar MH, Roth GA, et al. Temporal trends in ischemic heart disease mortality in 21 world regions, 1980 to 2010. Circulation. 2014; 129(14):1483-1492.
33. Moran AE, Forouzanfar MH, Roth GA, et al. The global burden of ischemic heart disease in 1990 and 2010. Circulation. 2014;129(14):1493-1501.
34. Murray CJ, Vos T, Lozano R, et al. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010. Lancet. 2012;380(9859):2197-2223.
35. Kazi DS, Garber AM, Shah RU, et al. Cost-effectiveness of genotype-guided and dual antiplatelet therapies in acute coronary syndrome. Ann Intern Med. 2014;160(4):221-232.
36. Khazeni N, Hutton DW, Garber AM, et al. Effectiveness and cost-effectiveness of vaccination against pandemic influenza (H1N1) 2009. Ann Intern Med. 2009;151(12):829-839.
37. Khazeni N, Hutton DW, Garber AM, Owens DK. Effectiveness and cost-effectiveness of expanded antiviral prophylaxis and adjuvanted vaccination strategies for an influenza A (H5N1) pandemic. Ann Intern Med. 2009;151(12):840-853.
38. USNational Library of Medicine. Label: Praluent-alirocumab injection, solution. http://dailymed.nlm .nih.gov/dailymed/drugInfo.cfmsetid=446f6b5c-0dd4-44ff-9bc2-c2b41f2806b4. Accessed September 2, 2015.
39. USNational Library of Medicine. Label: Repatha-evolocumab injection, solution. http://dailymed .nlm.nih.gov/dailymed/drugInfo.cfmsetid =709338ae-ab8f-44a9-b7d5-abaabec3493a. Accessed September 2, 2015.
40. Gidding SS, Champagne MA, de Ferranti SD, et al. The agenda for familial hypercholesterolemia: a scientific statement from the American Heart Association. Circulation. 2015;132(22):2167-2192.
41. Singh S, Bittner V. Familial hypercholesterolemia-epidemiology, diagnosis, and screening. Curr Atheroscler Rep. 2015;17(2):482.
42. Grundy SM. Statin discontinuation and intolerance: the challenge of lifelong therapy. Ann Intern Med. 2013;158(7):562-563.
43. Zhang H, Plutzky J, Skentzos S, et al. Discontinuation of statins in routine care settings. Ann Intern Med. 2013;158(7):526-534.
44. Sanofi and Regeneron announce FDA approval of Praluent (alirocumab) injection, the first PCSK9 inhibitor in the US, for the treatment of high LDL cholesterol in adult patients. http://en.sanofi.com/NasdaQ-OMX/local/press-releases/sanofi-and-regeneron-announce-1941221-24-07-2015!21-24-28.aspx. Accessed August 1, 2015.
45. UK National Health Service Medicines Information. New drugs online report for evolocumab. http://www.ukmi.nhs.uk/applications/ndo/record-view-open.aspnewDrugID=5828. Accessed November 1, 2015.
46. Amgen debuts Repatha in UK, with price at a huge discount to that in the USA. February 9, 2015. http://www.thepharmaletter.com/article/amgen-debuts-repatha-in-uk-with-price-at-a-huge-discount-to-that-in-usa. Accessed November 1, 2015.
47. Anderson JL, Heidenreich PA, Barnett PG, et al. ACC/AHA statement on cost/valuemethodology in clinical practice guidelines and performance measures. J AmColl Cardiol. 2014;63(21):2304-2322.
48. Office of the Assistant Secretary for Planning and Evaluation, Department of Health and Human Services. Observations on trends in prescription drug spending. https://aspe.hhs.gov/sites/default/files/pdf/187586/Drugspending.pdf. Accessed May 10, 2016.
49. Reinhardt U. Probing our moral values in health care: the pricing of specialty drugs. http://newsatjama.jama.com/2015/08/11/jama-forum-probing-our-moral-values-in-health-care-the-pricing-of-specialty-drugs/. Accessed August 17, 2015.
50. Newman CB, Tobert JA. Statin intolerance: reconciling clinical trials and clinical experience. JAMA. 2015;313(10):1011-1012.
51. Joy TR, Zou GY, Mahon JL. N-of-1 (single-patient) trials for statin-relatedmyalgia. Ann Intern Med. 2014;161(7):531-532.
52. The Price of Sovaldi and Its Impact on the US Health Care System. http://www.finance.senate.gov/download/the-price-of-sovaldi-and-its-impact-on-the-us-health-care-system-full-report. Accessed May 10, 2016.
53. Rheumatoid Arthritis: Background, New Development, Key Strategies. http://www .optum.com.br/content/dam/optum/Images/Thought%20Leadership/Rx/rheumatoid-arthritis-insight-report/M53018-L-RA-Insight%20Report-Live%20Links-FINAL.pdf. Accessed July 1, 2016.
54. Blackstone EA, Joseph PF. The economics of biosimilars. Am Health Drug Benefits. 2013;6(8): 469-478.
55. Mulcahy AW, Predmore Z, Mattke S. The Cost Savings Potential of Biosimilar Drugs in the United States: RAND Corporation Perspective. https://www .rand.org/content/dam/rand/pubs/perspectives/PE100/PE127/RAND-PE127.pdf. Accessed May 10, 2016.
56. NICE draft guidance recommends new drugs for cholesterol disorder. https://www.nice.org.uk/news/press-and-media/nice-draft-guidance-recommends-new-drugs-for-cholesterol-disorder. Accessed May 10, 2016.
57. Lazar LD, Pletcher MJ, Coxson PG, et al. Cost-effectiveness of statin therapy for primary prevention in a low-cost statin era. Circulation. 2011; 124(2):146-153.
58. Everett BM, Smith RJ, Hiatt WR. Reducing LDL with PCSK9 inhibitors - The clinical benefit of lipid drugs. N Engl J Med. 2015;373(17):1588-1591.